Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
45 hedge funds and large institutions have $122M invested in Kaleido Biosciences, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 24 increasing their positions, 4 reducing their positions, and 4 closing their positions.
500% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 4
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
10% more funds holding
Funds holding: 41 → 45 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
32% less capital invested
Capital invested by funds: $180M → $122M (-$58.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.63M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$805K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$771K |
| 4 |
Goldman Sachs
New York
|
+$710K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$371K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$2.54M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$753K |
| 3 |
KA
Kerrisdale Advisers
Miami,
Florida
|
-$546K |
| 4 |
BCM
Barometer Capital Management
Toronto,
Ontario, Canada
|
-$226K |
| 5 |
Millennium Management
New York
|
-$161K |
KLDO Hedge Fund Activity: Q4 2019 in Review
45 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q4 2019, worth a combined $122M — down 32% from $180M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new KLDO positions and 4 closed out — a net gain of 4 holders — while 24 added to existing stakes and 4 trimmed.
The largest buyer was BlackRock, adding an estimated $1.63M. The largest seller was Artal Group, cutting an estimated $2.54M.
- 45 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q4 2019, up from 41 in Q3 2019.
- Funds reported $122M of Kaleido Biosciences, Inc. Common Stock stock for Q4 2019, down 32% quarter-over-quarter.
- 8 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q4 2019 and 4 closed out, a net change of +4 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q4 2019 was BlackRock, an estimated $1.63M added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q4 2019 was Artal Group, an estimated $2.54M sold.
Based on aggregated 13F filings for Q4 2019.